Organogenesis to open $100M biotech facility in Rhode Island, will resume Dermagraft production

Organogenesis, a regenerative medicine company focused on wound care, is planning a new biomanufacturing facility in Smithfield, Rhode Island.

The expected $100M, 122,000 square-foot facility will accommodate manufacturing, laboratory, warehouse, and distribution operations, and resume production of its FDA-approved therapy for diabetic foot ulcers, Dermagraft.

Dermagraft is a human fibroblast-derived dermal substitute (HFDS) made of a cryopreserved, absorbable, three-dimensional polyglactin mesh substrate seeded with living neonatal dermal fibroblasts.

Here’s the Science Direct article explaining the product:
https://www.sciencedirect.com/topics/engineering/dermagraft?__cf_chl_tk=pCzEII_wrmJUjQ7f65ZO1HSGuqXmYASRyje_Ii.gyL8-1747967145-1.0.1.1-WERhJ27HgBMyldIKblxczQa.I9tfl3GXjJ724V9wwhE

That’s all, short one for today ☺.

Similar stories

Made Scientific Selected to Manufacture Columbia University’s NOVAKnee, a 3D Printed Knee Replacement Made of Stem Cells and ScaffoldsJun 10, 2026BioStem Technologies Receives 5 Patents for Placental AllograftsMay 20, 2026Kangstem Publishes Promising Phase 1 Results for Cord-Blood Derived Stem Cell Therapy in Knee Osteoarthritis, Post-MRI Data Suggest Potential Cartilage RegenerationMay 19, 2026Royal Biologics and Jellagen Bringing Jellyfish-Derived Collagen Type Zero to the US Regenerative Medicine MarketMay 17, 2026

Editor’s Picks

Century Therapeutics Reports Sustained Glucose Control With iPSC-Derived Islets in Diabetic Mice, IND SoonOct 20, 2026Umbilical Cord Mesenchymal Stem Cell Injections Lower Pain Scores More Than Hyaluronate in 50-Patient Severe Knee Osteoarthritis TrialOct 18, 2026Stempeutics Nabs US Patent for Osteoarthritis Treatment Combining Bone Marrow Stem Cells and Hyaluronic AcidOct 18, 2026Inside Cellular Intelligence: The Zuck-Backed AI Company That Acquired Novo’s Parkinson’s Cell TherapyOct 4, 2026